版本:
中国

BRIEF-Agile Therapeutics to resubmit Twirla NDA to FDA by Q2 2017-end

April 27 Agile Therapeutics Inc:

* Plans to resubmit its New Drug Application for Twirla to U.S. Food and Drug Administration by end of Q2 of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐